News

2:10 PMYahoo Finance

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's what it means for investors.

NVCR−2.3%

7:00 AMYahoo Finance

Novocure provides Regulatory update on U.S. FDA premarket approval application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

NVCR−2.3%

8:15 AMYahoo Finance

Don't Overlook NovoCure (NVCR) International revenue Trends while assessing the stock

NVCR−2.3%

9:43 PMYahoo Finance

NovoCure: 3 key Takeaways for long-term investors

NVCR−2.3%

4:12 AMYahoo Finance

NovoCure (NVCR) Q3 results spark margin turn debate

NVCR−2.3%

8:17 AMYahoo Finance

NovoCure stock is in focus after earnings beat and Slower Optune Pax launch

NVCR−2.3%

4:14 PMYahoo Finance

NovoCure Q3 earnings call highlights

NVCR−2.3%

2:43 PMYahoo Finance

NovoCure (NVCR) Q3 2026 earnings call transcript

NVCR−2.3%

11:44 AMYahoo Finance

NovoCure sinks 5% despite guidance raise as pancreatic cancer launch Access is “significantly limited”

NVCR−2.3%

7:35 AMYahoo Finance

NovoCure (NVCR) reports Q3 loss, tops revenue estimates

NVCR−2.3%

7:23 AMYahoo Finance

NovoCure: Q3 earnings snapshot

NVCR−2.3%

7:00 AMYahoo Finance

Novocure reports third quarter 2026 financial results and raises 2026 guidance

NVCR−2.3%

7:00 AMYahoo Finance

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic cancer through clinical trial collaboration and supply agreement

NVCR−2.3%